Joel Habener on GLP-1 Discovery for Diabetes & Obesity Treatment

Award Recognition

• 🏆 Joel Habener was deeply honored to be a co-recipient of the 2024 Frontiers of Knowledge Award.
• 👏 The award recognizes his contributions to the discovery of GLP-1 and its role in alleviating illnesses for millions globally.

Discovery of GLP-1

• 🔬 In 1979, his lab cloned the anglerfish proglucagon gene, identifying a glucagon-related peptide, later named GLP-1.
• 🧬 Subsequent cloning of mammalian pro-glucagon genes revealed the encoding of two GLPs, GLP-1 and GLP-2, in addition to glucagon.
• 💡 Svetlana Mojsov and Dan Drucker in his lab localized the biologically active peptide sequence to 31 amino acids (GLP-1 7-37).

Biological Function

• 🧪 GLP-1 7-37 is expressed in the intestine and pancreas, stimulating glucose-dependent insulin secretion.
• 🎯 These studies established GLP-1 as a gluco-incretin hormone, crucial for maintaining glucose levels and regulating appetite.

Therapeutic Applications

• 💊 GLP-1 was recognized as an effective treatment for type 2 diabetes due to its ability to stimulate the pancreas to produce its own insulin.
• 📈 During therapy for type 2 diabetes, patients experienced weight loss, leading to GLP-1's subsequent use for obesity and weight management.

Broader Impact

• ✨ The discoveries laid the foundation for a pharmacological revolution, offering new drugs for diabetes and significant weight loss.
• 🌱 GLP-1 treatments also show exciting therapeutic potential for neurological conditions like Parkinson's and Alzheimer's, and addiction disorders.